This work was supported by the Canadian Institutes of Health Research (CIHR), the Townsend Family, and Jack Brown and Family Alzheimer's Research Foundation (to W. S.). W. S. is the holder of the Canada Research Chair in Alzheimer's Disease. P. T.T. L. is supported by the Natural Sciences and Engineering Research Counsel and the Michael Smith Foundation for Health Research Scholarship.

1.	Fixation of mouse brains and cryosectioning
<ol>
<li>Transgenic mice are sacrificed using carbon dioxide gas, followed by decapitation and the brain extracted.</li>
<li>The brain is dissected longitudinally at the center. Half of the brain will be flash frozen on dry ice for biochemical analysis. The other will be submerged in 4% paraformaldehyde (PFA) for at least 48 hours at 4&deg;C.</li> 
<li>After fixation in 4% PFA for at least 48 hours, the hemi brain is transferred directly into 30% sucrose solution and placed at 4&deg;C. At the point, the hemi brain should be floating in the sucrose solution. When the hemi brain sank to the bottom, usually requiring about 48 hours, it is ready to be embedded in OCT for cryosectioning.</li>
<li>Before cryosectioning, mount a thin layer of OCT on the knob and allow to freeze at -20&deg;C. Remove the cerebellum from the rest of the hemi brain and place onto the layer of frozen OCT. Immediately cover the hemi brain with OCT and allow to slowly freeze at -20&deg;C. Once the OCT embedding the brain has turned opaque, it is ready to be sectioned.</li>
<li>Set the thickness of each section to 30 &mu;m. Collect each slice into a container with D'Olomos solution.</li>
</ol>
2.	Immunohistochemistry procedure for neuritic plaques (free floating sections)
<ol>
<li>Treat each section in 88% formic acid for 15 minutes. After formic acid treatment, the section will temporarily turn opaque and may appear to shrivel.</li>
<li>Remove each section into a plate and wash with Tx-PBS (0.3% Triton X-100 in PBS) for 5 min X 3 with gentle shaking.</li>
<li>Block Endogenous Peroxide blocking 0.5% H2O2 in Tx-PBS, RT 30 min with gentle shaking.</li>
<li>Wash section with Tx-PBS for 10 min X 3 with gentle shaking.</li>
<li>Block section with 5% non-fat skim milk dissolved in Tx-PBS at room temperature for 1 hour with gentle shaking.</li> 
<li>Incubate sections in primary antibody (Biotinylated 4G8, 1:500-1:2000, Signet) diluted in Tx-PBS containing 5% milk at 4&deg;C overnight with gentle shaking.</li>
<li>Wash section with Tx-PBS for 10 min X 3 with gentle shaking.</li>
<li>Prepare ABC solution following manufacturer's protocol (Elite ABC, Vector Laboratories,). Incubate sections in ABC mixture for 30 min with gentle shaking.</li> 
<li>Wash section with Tx-PBS for 10 min X 3 with gentle shaking.</li>
<li>Prepare 3,3'-diaminobenzidine tetrahydrochloride (DAB) (Vector Laboratories) following manufacturer's protocol. Incubate sections in DAB mixture for 5-10 min. At this point, you will observe a brownish color develop on each section.</li>
<li>Wash section with Tx-PBS for 10 min X 3 with gentle shaking.</li>
<li>Free-floating brain sections are mounted on gelatin coated slides, to help with tissue adhesion. Sections are then air dried followed by clearing with a series of xylene and mounted in Entellen.</li>
<li>Plaques are visualized under light microscopy at 40X magnification and are quantified by assessing the mean plaque count per slice for each mouse.</li>
</ol>
3.	Thioflavin S staining procedure for detection of neuritic plaques
<ol>
<li>Mouse sacrifice and brain extraction procedure are as indicated in sections 1.1 to 1.5.</li>
<li>Mount 4 to 5 hemi brain sections onto a glass slide and allow to completely air dry prior to staining.</li> 
<li>Wash slides with 70% Ethanol for 1 minute.</li>
<li>Wash slides with 80% Ethanol for 1 minute.</li>
<li>Incubate slides in filtered (0.2 &mu;m filter) thioflavin S solution (1% in 80% of Ethanol) for 15 minutes. (Thioflavin S solution needs to be filtered before each use). Note: protect thioflavin S from light and protect stained slides from light.</li>
<li>Wash slides with 80% Ethanol for 1 minute.</li>
<li>Wash slides with 70% Ethanol 1 minute.</li>
<li>Wash with distilled water twice.</li>
<li>Mount slides in aqueous mounting media and allow slides to dry in the dark for at least 2 hour, followed by sealing coverslip with clear nail polish. Stained sections should be stored in the dark at 4&deg;C.</li>
<li>The green fluorescence stained plaques could be visualized with fluorescent microscropy. Analyze slides within one week because the staining will fade with time.</li>
</ol>
4. Representative Results
In our recent study on the efficacy of the anti-epileptic drug and mood stabilizer valproic acid (VPA) to inhibit neuritic plaque formation, we used the above described immunostaining and thioflavin S staining procedures to identify neuritic plaques in AD model mice (3). Figure 1 represents a typical 9 month old APP23 transgenic mouse, stained with anti-A&beta; using biotinylated 4G8 and detected via the ABC method. Neuritic plaques are clearly labeled with the antibody and are indicated by the white arrows. Using thioflavin S staining, we detected neuritic plaque deposition 2 month old APP23xPS transgenic mice (Figure 2). Thioflavin S bound A&beta;-containing neuritic plaques appears green under fluorescence microscopy (indicated by white arrows). We showed that with VPA treatment, neuritic plaque formation is significantly reduced (3). In another study, we studied the molecular link underlying hypoxia and AD pathogenesis. Again, using both 4G8 anti-A&beta; immunohistochemistry staining and thioflavin S staining, we found that hypoxia facilitated the formation of A&beta; containing neuritic plaques (4).
<img src="/files/ftp_upload/2831/2831fig1.jpg" alt="Figure 1"/> 
Figure 1. Immunohistochemical analysis of neuritic plaque formation in AD transgenic mice. APP23 mice at the age of 9 months were sacrificed and were dissected, fixed, and sectioned. Neuritic plaques in the hippocampal were detected using an anti-A&beta; antibody 4G8 and were developed using the ABC and DAB methods. The plaques were visualized by light microscopy with 40X. White arrows point to A&beta; neuritic plaques. 
<img src="/files/ftp_upload/2831/2831fig2.jpg" alt="Figure 2"/> 
Figure 2. Thioflavin S staining of neuritic plaques in AD modeled mice. APP23xPS45 double transgenic mice at 8 weeks old were sacrificed and were dissected, fixed, and sectioned. Neuritic plagues in the hippocampal are were confirmed using thioflavin S fluorescent staining and visualized by microscopy at 40X magnification. White arrows indicate thioflavin S stained neuritic plaques.

<ol>
	<li>Glenner, G. G., Wong, C. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Alzheimer's+disease:+initial+report+of+the+purification+and+characterization+of+a+novel+cerebrovascular+amyloid+protein.">Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.</a> Biochem Biophys Res Commun. 120, 885-890 (1984).</li><li>Hardy, J., Selkoe, D. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+amyloid+hypothesis+of+Alzheimer's+disease:+progress+and+problems+on+the+road+to+therapeutics.">The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.</a> Science. 297, 353-356 (2002).</li><li>Qing, H., He, G., Ly, P. T., Fox, C. J., Staufenbiel, M., Cai, F., Zhang, Z., Wei, S., Sun, X., Chen, C. H., Zhou, W., Wang, K., Song, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Valproic+acid+inhibits+Abeta+production,+neuritic+plaque+formation,+and+behavioral+deficits+in+Alzheimer's+disease+mouse+models.">Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.</a> J Exp Med. 205, 2781-2789 (2008).</li><li>Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., Song, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hypoxia+facilitates+Alzheimer's+disease+pathogenesis+by+up-regulating+BACE1+gene+expression.">Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression.</a> Proc Natl Acad Sci U S A. 103, 18727-18732 (2006).</li></ol>

All experiments were conducted in accordance with The University of British Columbia Animal Care and Use committee and CIHR guidelines.

Immunohistochemistry using the biotinylated labeled 4G8 antibody stains neuritic plaques in AD modeled mice with specificity. The staining outcome allows quantification and comparison of plaque load between different treatment groups. There are several crucial steps that could affect the outcome. Because the hemi brains are not perfused prior to extraction from the skull, care should be used during the extraction process in order to prevent damages to the hemi brain. Moreover, since the hemi brain is passively perfused, we recommend incubating it in 4% PFA for at least 48 hours at 4&deg;C prior to submerging in the 30% sucrose solution. Alternatively, transcardial perfusion could be done prior to extracting the brain. If the brain is fixed properly, it should have a rubbery texture. In the case where the brain is not fixed properly, the sections will easily tear in the D'Olomos solution or during the staining procedures.
The 4G8 monoclonal antibody is reactive to amino acid residues 17-24 of A&beta; and recognized the epitope in the core sequence (VFFAE). Since 4G8 is derived from mouse species, it tends to give a higher background staining. Thus, we chose to incubate the sections at the indicated dilution with considerations to achieving a true signal while minimizing background staining. 
In addition to immunostaining for neuritic plaques detection using the 4G8 antibody, a thioflavin S staining method is also used to identify plaques. Thioflavin S is a homogenous dye mixture that results from methylation of dehydrothiotoluidine with sulfonic acid. Thioflavin S non-selectively binds beta sheet contents of proteins, such as those in amyloid oligomers. Upon binding, thioflavin undergoes a characteristic blue shift of its emission spectrum. Conversely thioflavin S binding to the monomeric forms will not elicit a blue shift and could not be detected with florescent microscope. Thioflavin S staining provides a quick alternative to screen for amyloid as the intensity of fluorescence allows good visualization of small amounts of amyloid deposits. However, one drawback about thioflavin S staining is the lack of specificity. Many other tissue components including containing extensive beta sheets, such as fibrinoids, hyaline, keratin, etc, have a rather affinity for this dye.

<table border="1">
	<tbody>
 	<tr>	
 	<th>Name of the reagent and equipment</th>
 <th>Company</th>
 <th>Catalogue number</th>
 
 </tr>
 <tr>
 	<td>Paraformaldehyde</td>
 <td>Sigma-Aldrich</td>
 <td>P6148-1KG</td>
 </tr>
 <tr>
 	<td>Polyvinylpyrrolidene</td>
 <td>Sigma-Aldrich</td>
 <td>PVP40-100G</td>
 </tr>

 <tr>
 	<td>Sucrose</td>
 <td>Fisher Scientific</td>
 <td>S5-3</td>
 </tr>

 <tr>
 	<td>Ethylene glycol</td>
 <td>Sigma-Aldrich</td>
 <td>324558-2L</td>
 </tr>

 <tr>
 	<td>Tissue-Tek O.C.T. Compound</td>
 <td>Sakura</td>
 <td>4583</td>
 </tr>

 <tr>
 	<td>88% formic acid</td>
 <td>Fisher Scientific</td>
 <td>A118P-500</td>
 </tr>

 <tr>
 	<td>Triton X-100</td>
 <td>ICN Biomedicals</td>
 <td>807426</td>
 </tr>
 <tr>
 	<td>H2O2</td>
 <td>Sigma-Aldrich</td>
 <td>H-1009</td>
 </tr>
 <tr>
 	<td>Biotin Labeled 4G8 Antibody</td>
 <td>Cedarlane</td>
 <td>SIG-39240-500</td>
 </tr>
 <tr>
 	<td>Elite ABC kit</td>
 <td>Vector</td>
 <td>PK-6100</td>
 </tr>
 <tr>
 	<td>Imm PACT DAB</td>
 <td>Vector</td>
 <td>SK-4105</td>
 </tr>
 <tr>
 	<td>Xylene</td>
 <td>Fisher Scientific</td>
 <td>X4-4</td>
 </tr>
 <tr>
 	<td>Entellan</td>
 <td>EM science</td>
 <td>65037-71</td>
 </tr>
 <tr>
 	<td>Superfrost* Plus Microscope Slides</td>
 <td>Fisher Scientific</td>
 <td>12-550-15</td>
 </tr>
 <tr>
 	<td>Cryostat</td>
 <td>Leica</td>
 <td>CM-3050-S</td>
 </tr>
 <tr>
 	<td>MX35 Premier microtome blade</td>
 <td>Thermo Scientific</td>
 <td>3052835</td>
 </tr>
 <tr>
 	<td>Thioflavin S</td>
 <td>Sigma-Aldrich</td>
 <td>T1892-25G</td>
 </tr>
 </tbody>
</table>

detection of neuritic plaques in alzheimer's disease mouse model

Alzheimer's disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaque formation is one of the pathological hallmarks of Alzheimer's disease. The central component of neuritic plaques is a small filamentous protein called amyloid &beta; protein (A&beta;)1, which is derived from sequential proteolytic cleavage of the beta-amyloid precursor protein (APP) by &beta;-secretase and &gamma;-secretase. The amyloid hypothesis entails that A&gamma;-containing plaques as the underlying toxic mechanism in AD pathology2. The postmortem analysis of the presence of neuritic plaque confirms the diagnosis of AD. To further our understanding of A&gamma; neurobiology in AD pathogenesis, various mouse strains expressing AD-related mutations in the human APP genes were generated. Depending on the severity of the disease, these mice will develop neuritic plaques at different ages. These mice serve as invaluable tools for studying the pathogenesis and drug development that could affect the APP processing pathway and neuritic plaque formation. In this protocol, we employ an immunohistochemical method for specific detection of neuritic plaques in AD model mice. We will specifically discuss the preparation from extracting the half brain, paraformaldehyde fixation, cryosectioning, and two methods to detect neurotic plaques in AD transgenic mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thiofalvin S staining method.

Watch this Scientific Journal Video about Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model at JoVE.com

Detection of Neuritic Plaques in Alzheimer&#039;s Disease Mouse Model

One of the pathological characteristics of AD is the formation of Amyloid &#x03B2; protein positive neuritic plaques. In this protocol we describe two methods to detect neuritic plaques in transgenic AD model mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thioflavin S staining method.

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Alzheimer's disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaque formation is one of the pathological hallmarks ...

detection-of-neuritic-plaques-in-alzheimer-s-disease-mouse-model

Research

JoVE Journal

Neuroscience

36.4K Views.  The University of British Columbia. One of the pathological characteristics of AD is the formation of Amyloid β protein positive neuritic plaques. In this protocol we describe two methods to detect neuritic plaques in transgenic AD model mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thioflavin S staining method.

Video: Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Preparation of Oligomeric &beta;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Impairment of synaptic connections is likely to underlie the subtle amnesic changes occurring at the early stages of Alzheimer s Disease (AD). &beta;-amyloid (A&beta;), a peptide produced in high amounts in AD, is known to reduce Long-Term Potentiation (LTP), a cellular correlate of learning and memory. Indeed, LTP impairment caused by A&beta; is a useful experimental paradigm for studying synaptic dysfunctions in AD models and for screening drugs capable of mitigating or reverting such synaptic impairments. Studies have shown that A&beta; produces the LTP disruption preferentially via its oligomeric form. Here we provide a detailed protocol for impairing LTP by perfusion of oligomerized synthetic A&beta;1-42 peptide onto acute hippocampal slices. In this video, we outline a step-by-step procedure for the preparation of oligomeric A&beta;1-42. Then, we follow an individual experiment in which LTP is reduced in hippocampal slices exposed to oligomerized A&beta;1-42 compared to slices in a control experiment where no A&beta;1-42 exposure had occurred.

Preparation of Oligomeric &amp;#946;-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

One feature of Alzheimer's Disease is the elevation of A&beta;1-42 peptide. Here we provide a protocol for preparing synthetic A&beta;1-42 oligomers, which impairs hippocampal Long-Term Potentiation, a cellular correlate of memory. This procedure is useful for investigating mechanisms of A&beta;-induced pathology and drug screening.

Impairment of synaptic connections is likely to underlie the subtle amnesic changes occurring at the early stages of Alzheimer s Disease (AD). ...

Selection of Aptamers for Amyloid &beta;-Protein, the Causative Agent of Alzheimer&#39;s Disease

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis difficult1. Definite AD diagnosis is achieved only postmortem, thus establishing presymptomatic, early diagnosis of AD is crucial for developing and administering effective therapies2,3.
Amyloid &beta;-protein (A&beta;) is central to AD pathogenesis. Soluble, oligomeric A&beta; assemblies are believed to affect neurotoxicity underlying synaptic dysfunction and neuron loss in AD4,5. Various forms of soluble A&beta; assemblies have been described, however, their interrelationships and relevance to AD etiology and pathogenesis are complex and not well understood6. Specific molecular recognition tools may unravel the relationships amongst A&beta; assemblies and facilitate detection and characterization of these assemblies early in the disease course before symptoms emerge. Molecular recognition commonly relies on antibodies. However, an alternative class of molecular recognition tools, aptamers, offers important advantages relative to antibodies7,8. Aptamers are oligonucleotides generated by in-vitro selection: systematic evolution of ligands by exponential enrichment (SELEX)9,10. SELEX is an iterative process that, similar to Darwinian evolution, allows selection, amplification, enrichment, and perpetuation of a property, e.g., avid, specific, ligand binding (aptamers) or catalytic activity (ribozymes and DNAzymes).
Despite emergence of aptamers as tools in modern biotechnology and medicine11, they have been underutilized in the amyloid field. Few RNA or ssDNA aptamers have been selected against various forms of prion proteins (PrP)12-16. An RNA aptamer generated against recombinant bovine PrP was shown to recognize bovine PrP-&beta;17, a soluble, oligomeric, &beta;-sheet-rich conformational variant of full-length PrP that forms amyloid fibrils18. Aptamers generated using monomeric and several forms of fibrillar &beta;2-microglobulin (&beta;2m) were found to bind fibrils of certain other amyloidogenic proteins besides &beta;2m fibrils19. Ylera et al. described RNA aptamers selected against immobilized monomeric A&beta;4020. Unexpectedly, these aptamers bound fibrillar A&beta;40. Altogether, these data raise several important questions. Why did aptamers selected against monomeric proteins recognize their polymeric forms? Could aptamers against monomeric and/or oligomeric forms of amyloidogenic proteins be obtained? To address these questions, we attempted to select aptamers for covalently-stabilized oligomeric A&beta;4021 generated using photo-induced cross-linking of unmodified proteins (PICUP)22,23. Similar to previous findings17,19,20, these aptamers reacted with fibrils of A&beta; and several other amyloidogenic proteins likely recognizing a potentially common amyloid structural aptatope21. Here, we present the SELEX methodology used in production of these aptamers21.

Selection of Aptamers for Amyloid &amp;#946;-Protein, the Causative Agent of Alzheimer&#039;s Disease

Aptamers are short ribo-/deoxyribo-oligonucleotides selected by in-vitro evolution methods based on affinity for a specific target. Aptamers are molecular recognition tools with versatile therapeutic, diagnostic, and research applications. We demonstrate methods for selection of aptamers for amyloid &beta;-protein, the causative agent of Alzheimer's disease.

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis ...

Morris Water Maze Test for Learning and Memory Deficits in Alzheimer&#39;s Disease Model Mice

The Morris Water Maze (MWM) was first established by neuroscientist Richard G. Morris in 1981 in order to test hippocampal-dependent learning, including acquisition of spatial memoryand long-term spatial memory 1. The MWM is a relatively simple procedure typically consisting of six day trials, the main advantage being the differentiation between the spatial (hidden-platform) and non-spatial (visible platform) conditions 2-4. In addition, the MWM testing environment reduces odor trail interference 5. This has led the task to be used extensively in the study of the neurobiology and neuropharmacology of spatial learning and memory. The MWM plays an important role in the validation of rodent models for neurocognitive disorders such as Alzheimer&#x2019;s Disease 6, 7. In this protocol we discussed the typical procedure of MWM for testing learning and memory and data analysis commonly used in Alzheimer&#x2019;s disease transgenic model mice.

Morris Water Maze Test for Learning and Memory Deficits in Alzheimer&#039;s Disease Model Mice

The Morris Water Maze is a behavioral task to test hippocampal-dependent learning and memory. It has been widely used in the study of neurobiology, neuropharmacology and neurocognitive disorders in rodent models.

The Morris Water Maze (MWM) was first established by neuroscientist Richard G. Morris in 1981 in order to test hippocampal-dependent learning, including ...

Detection of Microregional Hypoxia in Mouse Cerebral Cortex by Two-photon Imaging of Endogenous NADH Fluorescence

The brain's ability to function at high levels of metabolic demand depends on continuous oxygen supply through blood flow and tissue oxygen diffusion. Here we present a visualized experimental and methodological protocol to directly visualize microregional tissue hypoxia and to infer perivascular oxygen gradients in the mouse cortex. It is based on the non-linear relationship between nicotinamide adenine dinucleotide (NADH) endogenous fluorescence intensity and oxygen partial pressure in the tissue, where observed tissue NADH fluorescence abruptly increases at tissue oxygen levels below 10 mmHg1. We use two-photon excitation at 740 nm which allows for concurrent excitation of intrinsic NADH tissue fluorescence and blood plasma contrasted with Texas-Red dextran. The advantages of this method over existing approaches include the following: it takes advantage of an intrinsic tissue signal and can be performed using standard two-photon in vivo imaging equipment; it permits continuous monitoring in the whole field of view with a depth resolution of ~50 &mu;m. We demonstrate that brain tissue areas furthest from cerebral blood vessels correspond to vulnerable watershed areas which are the first to become functionally hypoxic following a decline in vascular oxygen supply. This method allows one to image microregional cortical oxygenation and is therefore useful for examining the role of inadequate or restricted tissue oxygen supply in neurovascular diseases and stroke.

Here we describe a method to directly visualize microregional tissue hypoxia in the mouse cortex in vivo. It is based on concurrent two-photon imaging of nicotinamide adenine dinucleotide (NADH) and the cortical microcirculation. This method is useful for high resolution analysis of tissue oxygen supply.

The brain's ability to function at high levels of metabolic demand depends on continuous oxygen supply through blood flow and tissue oxygen diffusion. ...

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Alzheimer&#8217;s disease is a neurodegenerative disease affecting the aging population. A key neuropathological feature of the disease is the over-production of amyloid-beta and the deposition of amyloid-beta plaques in brain regions of the afflicted individuals. Throughout the years scientists have generated numerous Alzheimer&#8217;s disease mouse models that attempt to replicate the amyloid-beta pathology. Unfortunately, the mouse models only selectively mimic the disease features. Neuronal death, a prominent effect in the brains of Alzheimer&#8217;s disease patients, is noticeably lacking in these mice. Hence, we and others have employed a method of directly infusing soluble oligomeric species of amyloid-beta - forms of amyloid-beta that have been proven to be most toxic to neurons - stereotaxically into the brain. In this report we utilize male C57BL/6J mice to document this surgical technique of increasing amyloid-beta levels in a select brain region. The infusion target is the dentate gyrus of the hippocampus because this brain structure, along with the basal forebrain that is connected by the cholinergic circuit, represents one of the areas of degeneration in the disease. The results of elevating amyloid-beta in the dentate gyrus via stereotaxic infusion reveal increases in neuron loss in the dentate gyrus within 1 week, while there is a concomitant increase in cell death and cholinergic neuron loss in the vertical limb of the diagonal band of Broca of the basal forebrain. These effects are observed up to 2 weeks. Our data suggests that the current amyloid-beta infusion model provides an alternative mouse model to address region specific neuron death in a short-term basis. The advantage of this model is that amyloid-beta can be elevated in a spatial and temporal manner.

Here, we present a protocol for direct stereotaxic brain infusion of amyloid-beta. This methodology provides an alternative in vivo mouse model to address the short-term effects of amyloid-beta on brain neurons.

Alzheimer&#8217;s disease is a neurodegenerative disease affecting the aging population. A key neuropathological feature of the disease is the ...

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

In neuroimaging, functional magnetic resonance imaging (fMRI) measures the blood-oxygenation-level dependent (BOLD) signal in the brain. The degree of correlation of the BOLD signal in spatially independent regions of the brain defines the functional connectivity of those regions. During a cognitive fMRI task, a psychophysiological interaction (PPI) analysis can be used to examine changes in the functional connectivity during specific contexts defined by the cognitive task. An example of such a task is one that engages the memory system, asking participants to learn pairs of unrelated words (encoding) and recall the second word in a pair when presented with the first word (retrieval). In the present study, we used this type of associative memory task and a generalized PPI (gPPI) analysis to compare changes in hippocampal connectivity in older adults who are carriers of the Alzheimer's disease (AD) genetic risk factor apolipoprotein-E epsilon-4 (APOE&#949;4). Specifically, we show that the functional connectivity of subregions of the hippocampus changes during encoding and retrieval, the two active phases of the associative memory task. Context-dependent changes in functional connectivity of the hippocampus were significantly different in carriers of APOE&#949;4 compared to non-carriers. PPI analyses make it possible to examine changes in functional connectivity, distinct from univariate main effects, and to compare these changes across groups. Thus, a PPI analysis may reveal complex task effects in specific cohorts that traditional univariate methods do not capture. PPI analyses cannot, however, determine directionality or causality between functionally connected regions. Nevertheless, PPI analyses provide powerful means for generating specific hypotheses regarding functional relationships, which can be tested using causal models. As the brain is increasingly described in terms of connectivity and networks, PPI is an important method for analyzing fMRI task data that is in line with the current conception of the human brain.

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer&#039;s Disease

This manuscript describes how to implement a psychophysiological interaction analysis to reveal task-dependent changes in functional connectivity between a selected seed region and voxels in other regions of the brain. Psychophysiological interaction analysis is a popular method to examine task effects on brain connectivity, distinct from traditional univariate activation effects.

In neuroimaging, functional magnetic resonance imaging (fMRI) measures the blood-oxygenation-level dependent (BOLD) signal in the brain. The degree of ...

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Neurotransmitter disruption is often a key component of diseases of the central nervous system (CNS), playing a role in the pathology underlying Alzheimer's disease, Parkinson's disease, depression, and anxiety. Traditionally, microdialysis has been the most common (lauded) technique to examine neurotransmitter changes that occur in these disorders. But because microdialysis has the ability to measure slow 1-20 minute changes across large areas of tissue, it has the disadvantage of invasiveness, potentially destroying intrinsic connections within the brain and a slow sampling capability. A relatively newer technique, the microelectrode array (MEA), has numerous advantages for measuring specific neurotransmitter changes within discrete brain regions as they occur, making for a spatially and temporally precise approach. In addition, using MEAs is minimally invasive, allowing for measurement of neurotransmitter alterations in vivo. In our laboratory, we have been specifically interested in changes in the neurotransmitter, glutamate, related to Alzheimer's disease pathology. As such, the method described here has been used to assess potential hippocampal disruptions in glutamate in a transgenic mouse model of Alzheimer's disease. Briefly, the method used involves coating a multi-site microelectrode with an enzyme very selective for the neurotransmitter of interest and using self-referencing sites to subtract out background noise and interferents. After plating and calibration, the MEA can be constructed with a micropipette and lowered into the brain region of interest using a stereotaxic device. Here, the method described involves anesthetizing rTg(TauP301L)4510 mice and using a stereotaxic device to precisely target sub-regions (DG, CA1, and CA3) of the hippocampus.

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer&#039;s Mouse Models

Here, we describe the setup, software navigation, and data analysis for a spatially and temporally precise method of measuring tonic and phasic extracellular glutamate changes in vivo using enzyme-linked microelectrode arrays (MEA).

Neurotransmitter disruption is often a key component of diseases of the central nervous system (CNS), playing a role in the pathology underlying ...

Neurobehavioral Assessments in a Mouse Model of Neonatal Hypoxic-ischemic Brain Injury

We performed unilateral carotid artery occlusion on CD-1 mice to create a neonatal hypoxic-ischemic (HI) model and investigated the effects of neonatal HI brain injury by studying neurobehavioral functions in these mice compared to non-operated (i.e., normal) mice. During the study, Rice-Vannucci&#39;s method was used to induce neonatal HI brain damage in postnatal day 7-10 (P7-10) mice. The HI operation was performed on the pups by unilateral carotid artery ligation and exposure to hypoxia (8% O2 and 92% N2 for 90 min). One week after the operation, the damaged brains were evaluated with the naked eye through the semi-transparent skull and were categorized into subgroups based on the absence (&#34;no cortical injury&#34; group) or presence (&#34;cortical injury&#34; group) of cortical injury, such as a lesion in the right hemisphere. On week 6, the following neurobehavioral tests were performed to evaluate the cognitive and motor functions: passive avoidance task (PAT), ladder walking test, and grip strength test. These behavioral tests are helpful in determining the effects of neonatal HI brain injury and are used in other mouse models of neurodegenerative diseases. In this study, neonatal HI brain injury mice showed motor deficits that corresponded to right hemisphere damage. The behavioral test results are relevant to the deficits observed in human neonatal HI patients, such as cerebral palsy or neonatal stroke patients. In this study, a mouse model of neonatal HI brain injury was established and showed different degrees of motor deficits and cognitive impairment compared to non-operated mice. This work provides basic information on the HI mouse model. MRI images demonstrate the different phenotypes, separated according to the severity of brain damage by motor and cognitive tests.

We performed unilateral carotid artery occlusion on postnatal day 7-10 CD-1 mouse pups to create a neonatal hypoxic-ischemic (HI) model and investigated the effects of HI brain injury. We studied neurobehavioral functions in these mice compared to non-operated normal mice.

We performed unilateral carotid artery occlusion on CD-1 mice to create a neonatal hypoxic-ischemic (HI) model and investigated the effects of neonatal HI ...

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Deposition of amyloid beta protein (A&#946;) in extra- and intracellular spaces is one of the hallmark pathologies of Alzheimer&#39;s disease (AD). Therefore, detection of the presence of A&#946; in AD brain tissue is a valuable tool for developing new treatments to prevent the progression of AD. Several classical amyloid binding dyes, fluorochrome, imaging probes, and A&#946;-specific antibodies have been used to detect A&#946; histochemically in AD brain tissue. Use of these compounds for A&#946; detection is costly and time consuming. However, because of its intense fluorescent activity, high-affinity, and specificity for A&#946;, as well as structural similarities with traditional amyloid binding dyes, curcumin (Cur) is a promising candidate for labeling and imaging of A&#946; plaques in postmortem brain tissue. It is a natural polyphenol from the herb Curcuma longa. In the present study, Cur was used to histochemically label A&#946; plaques from both a genetic mouse model of 5x familial Alzheimer&#39;s disease (5xFAD) and from human AD tissue within a minute. The labeling capability of Cur was compared to conventional amyloid binding dyes, such as thioflavin-S (Thio-S), Congo red (CR), and Fluoro-jade C (FJC), as well as A&#946;-specific antibodies (6E10 and A11). We observed that Cur is the most inexpensive and quickest way to label and image A&#946; plaques when compared to these conventional dyes and is comparable to A&#946;-specific antibodies. In addition, Cur binds with most A&#946; species, such as oligomers and fibrils. Therefore, Cur could be used as the most cost-effective, simple, and quick fluorochrome detection agent for A&#946; plaques.

Curcumin is an ideal fluorophore for labeling and imaging of amyloid beta protein plaques in brain tissue due to its preferential binding to amyloid beta protein as well as its structural similarities with other traditional amyloid binding dyes. It can be used to label and image amyloid beta protein plaques more efficiently and inexpensively than traditional methods.

Deposition of amyloid beta protein (A&#946;) in extra- and intracellular spaces is one of the hallmark pathologies of Alzheimer&#39;s disease (AD). ...

Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain

The length of cholinergic or other neuronal axons in various brain regions are often correlated with the specific function of the region. Stereology is a useful method to quantify neuronal profiles of various brain structures. Here we provide a software-based stereology protocol to estimate the total length of cholinergic fibers in the nucleus basalis of Meynert (NBM) of the basal forebrain. The method uses a space ball probe for length estimates. The cholinergic fibers are visualized by choline acetyltransferase (ChAT) immunostaining with the horseradish peroxidase-diaminobenzidine (HRP-DAB) detection system. The staining protocol is also valid for fiber and cell number estimation in various brain regions using stereology software. The stereology protocol can be used for estimation of any linear profiles such as cholinoceptive fibers, dopaminergic/catecholaminergic fibers, serotonergic fibers, astrocyte processes, or even vascular profiles.

Neuronal fiber length within a three-dimensional structure of a brain region is a reliable parameter to quantify specific neuronal structural integrity or degeneration. This article details a stereological quantification method to measure cholinergic fiber length within the nucleus basalis of Meynert in mice as an example.

The length of cholinergic or other neuronal axons in various brain regions are often correlated with the specific function of the region. Stereology is a ...